News & Updates

Treatment of gestational diabetes before 20 weeks’ gestation appears to lead to a modestly lower incidence of a composite of adverse neonatal outcomes as compared with no-immediate treatment, with no substantial differences noted for pregnancy-related hypertension or neonatal lean body mass, as reported in a study.

Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) albiglutide results in fewer cardiovascular events, irrespective of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, among patients with type 2 diabetes (T2D) and cardiovascular disease, according to the post hoc analysis of Harmony Outcomes*.

Eating nuts on a regular basis provides neuroprotective benefits to older adults who are overweight or obese, have metabolic syndrome, and are predisposed to memory loss or confusion, results of a cohort study have shown.

Adherence to a personalized calorie-restricted, weight-loss diet falls short of reducing glycaemic variability (GV) or glycated haemoglobin (HbA1c) relative to a one-size-fits-all low-fat (standardized) diet among patients with prediabetes and moderately controlled type 2 diabetes, a study has shown.

In pregnant women with obesity, supplementation with multi-strain probiotics does not appear to have favourable effects on the metabolic or inflammatory biomarkers in mothers and on the body composition of their offspring, according to a study.

Synbiotics V5 and V7 effectively reduce body weight in individuals with obesity or overweight undergoing lifestyle modification, as shown in a study.

The presence of endometriosis does not appear to contribute to an increased risk of type 2 diabetes in women, according to a study.

For postmenopausal women with a history of gestational diabetes, delivering high birth weight infants or hypertensive disorders of pregnancy poses a heightened risk of developing type 2 diabetes (T2D) in the future, according to a study.